Stephen J Fuller
Overview
Explore the profile of Stephen J Fuller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajakumar G, Cagigas M, Wang T, Pan A, Pelaia T, Fuller S, et al.
Ageing Res Rev
. 2024 Oct;
102:102531.
PMID: 39396675
Background: Insulin-like growth factor (IGF)-1 plays a role in aging and cancer biology, with fasting known to reduce serum IGF-1 levels in human adults. However, the impact of ad libitum...
2.
Bhattacharyya P, Christopherson R, Skarratt K, Fuller S
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001403
B cells are central to the adaptive immune response and provide long-lasting immunity after infection. B cell activation is mediated by the surface membrane-bound B cell receptor (BCR) following recognition...
3.
Guggemos J, Fuller S, Skarratt K, Mayer B, Schneider E
Front Immunol
. 2024 Jul;
15:1352789.
PMID: 38966639
Introduction: Extracellular ATP (eATP) released from damaged cells activates the P2X7 receptor (P2X7R) ion channel on the surface of surrounding cells, resulting in calcium influx, potassium efflux and inflammasome activation....
4.
Zilberg C, Ferguson A, Lyons J, Gupta R, Fuller S, Damian D
J Dermatol
. 2024 Jan;
51(3):353-364.
PMID: 38291978
Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that is associated with an increased risk of developing cutaneous malignancies. Clinical outcomes for these malignancies, including melanoma and keratinocyte cancers...
5.
De Salis S, Chen J, Skarratt K, Fuller S, Balle T
Purinergic Signal
. 2023 Nov;
20(4):431-447.
PMID: 38032425
P2X7 receptors (P2X7Rs) are membrane-bound ATP-gated ion channels that are composed of three subunits. Different subunit structures may be expressed due to alternative splicing of the P2RX7 gene, altering the...
6.
Bhattacharyya P, Schemann K, Min S, Sullivan D, Fuller S
Med J Aust
. 2023 Oct;
219(10):475-481.
PMID: 37875282
Objectives: To examine the relationship between vitamin C status and demographic factors in New South Wales on the basis of serum vitamin C test results undertaken at the central pathology...
7.
Bhattacharyya P, Christopherson R, Skarratt K, Chen J, Balle T, Fuller S
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296844
B cells are central to the adaptive immune response, providing long lasting immunity after infection. B cell activation is mediated by a cell surface B cell receptor (BCR) following recognition...
8.
Sluyter R, Adriouch S, Fuller S, Nicke A, Sophocleous R, Watson D
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175933
The P2X7 receptor is a trimeric ligand-gated cation channel activated by extracellular adenosine 5'-triphosphate. The study of animals has greatly advanced the investigation of P2X7 and helped to establish the...
9.
Allison E, Edirimanne S, Matthews J, Fuller S
Oncol Ther
. 2022 Dec;
11(1):27-48.
PMID: 36484945
Introduction: Tumor-associated macrophages (TAMs) in breast cancer are associated with a poor prognosis. Early studies of TAMs were largely limited to the pan-macrophage marker CD68, however, more recently, an increasing...
10.
Alharbi H, Hardyman M, Cull J, Markou T, Cooper S, Glennon P, et al.
Clin Sci (Lond)
. 2022 Nov;
136(22):1661-1681.
PMID: 36331065
Cardiac hypertrophy is necessary for the heart to accommodate an increase in workload. Physiological, compensated hypertrophy (e.g. with exercise) is reversible and largely due to cardiomyocyte hypertrophy. Pathological hypertrophy (e.g....